---
title: O.C.G.A. § 33-24-59.19. Coverage for treatment of burns with skin substitutes utilizing cryopreserved cadaver derived skin tissue.
collection: code
id: 33-24-59.19
cite_as: O.C.G.A. § 33-24-59.19 (2025)
canonical_url: https://georgiacommons.org/code/33-24-59.19
md_url: https://georgiacommons.org/code/33-24-59.19.md
text_url: https://georgiacommons.org/code/33-24-59.19/text
source_url: https://www.legis.ga.gov/api/document/docs/default-source/joint-features-document-library/t33-ch23-65-(v25)-2020-pdf.pdf?sfvrsn=68297_0#page=375
date: 2025
status: active
corpus_version: 2025-supplement-89aa39ab3c68
license: CC0-1.0
publisher: Georgia Commons, an independent project of Georgia Civic Data. Not the State of Georgia. Not legal advice.
up: https://georgiacommons.org/code/33-24.md
previous: https://georgiacommons.org/code/33-24-59.18.md
next: https://georgiacommons.org/code/33-24-59.20.md
index: https://georgiacommons.org/code/index.md
version: the only printed version
in_force: true
current_through: Including Acts of the 2025 Regular Session of the General Assembly
heading_path: INSURANCE / INSURANCE GENERALLY / GENERAL PROVISIONS
extraction_warnings:
  - dehyphenation_unverified:inves-tigational
---

# O.C.G.A. § 33-24-59.19. Coverage for treatment of burns with skin substitutes utilizing cryopreserved cadaver derived skin tissue.

No health benefit policy issued, delivered, or renewed in this state that, as a provision of hospital, medical, or surgical services, directly or indirectly covers the treatment and management of burns shall limit or exclude coverage for such treatment on the basis that the use of cryopreserved cadaver derived skin tissue is an experimental or investigational medical treatment.

## History

Code 1981, § 33-24-59.19, enacted by Ga. L. 2015, p. 1317, § 1/HB 409.

## Code Commission Notes

Pursuant to Code Section 28-9-5, in 2015, Code Section 33-24-59.18, as enacted by Ga. L. 2015, p. 1317, § 1/HB 409, was redesignated as Code Section 33-24-59.19.

## Law Reviews

For article, ‘‘Reforming Regenerative Medicine Regulation,’’ see 34 Ga. St. U. L. Rev. 631 (2018).